BioNxt Solutions Reports Progress on BNT23001 Development for Multiple Sclerosis Treatment
VANCOUVER, BC / ACCESSWIRE / December 9, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, has achieved key milestones in the development of BNT23001, its proprietary sublingual thin-film (OFD) formulation of Cladribine for the treatment of Multiple Sclerosis (MS). These achievements in 2024 lay the groundwork for clinical trials and regulatory submissions in 2025, reinforcing BioNxt's commitment to advancing patient-centric therapeutic solutions.
2024 Milestones: Establishing a Strong Foundation for Cladribine Thin-Film Development
Preclinical Success: BNT23001 demonstrated high absorption rates of Cladribine through sublingual delivery in pharmacokinetic (PK) studies conducted in animal models. These studies confirmed the product's bioequivalence to the originator therapy, Mavenclad®, and validated the thin-film's rapid absorption and safety profile. Toxicity studies further demonstrated no adverse local effects, highlighting the viability of the sublingual delivery approach.
Advancements in Manufacturing: BioNxt successfully transferred the BNT23001 production process to its GMP-certified manufacturing partner, Gen-Plus GmbH & Co KG in Munich (Germany), ensuring readiness for clinical batch production. This milestone supports the Company's plan to initiate clinical trials in 2025 with reliable, high-quality product supply.
Strengthened Intellectual Property Position: A favorable International Preliminary Report on Patentability (IPRP) confirmed BNT23001's novelty, inventive step, and industrial applicability, underscoring its unique value in MS treatment. The Company has initiated patent nationalization in major jurisdictions, including Europe, the United States, and Canada, with patent grants anticipated in several regions by mid-2025.
2025 Roadmap: Advancing BNT23001 into Clinical Trials
Manufacturing Clinical Batches: BioNxt will complete GMP manufacturing and Qualified Person (QP) release of clinical trial batches in the second quarter of 2025. This step is critical for the successful initiation of human studies.
Regulatory Filings and Approvals: The Company plans to submit the Investigational Medicinal Product Dossier (IMPD) to European regulatory authorities by mid-2025, paving the way for clinical trial approval. These regulatory submissions will include data from preclinical studies and stability assessments conducted at the manufacturing site.
Clinical Study to Validate Performance: BioNxt aims to launch a pilot clinical study in the latter half of 2025. This trial will compare the efficacy, bioavailability, and safety of BNT23001 to Mavenclad®, the originator tablet product, positioning the thin-film formulation as a patient-friendly alternative.
Ongoing Patent Protection: In addition to continuing the patent nationalization process, BioNxt expects granted patents in key regions to strengthen its intellectual property portfolio and provide competitive advantages as the product moves toward commercialization.
BNT23001: Advancing Toward Clinical Validation for MS Treatment
BNT23001 offers a novel approach to MS management by addressing limitations in traditional oral therapies. Its sublingual thin-film format provides:
• Convenience: Easy-to-use and portable, ideal for patients with difficulty swallowing or active lifestyles.
• Rapid Absorption: Direct delivery through the sublingual mucosa for faster therapeutic action.
• Improved Compliance: A patient-friendly alternative designed to enhance adherence to prescribed regimens.
By delivering these advantages, BNT23001 aligns with BioNxt's mission to improve outcomes for patients living with chronic diseases like MS.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co-Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 780-818-6422
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding "Forward-Looking" Information
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the development, testing, regulatory approval, and commercialization of BNT23001, as well as projected milestones for 2025. These statements are based on current expectations and assumptions but involve risks and uncertainties that could cause actual results to differ materially. These risks include clinical trial outcomes, regulatory delays, manufacturing challenges, intellectual property issues, market competition, and changes in laws or market conditions. The Company undertakes no obligation to update or revise forward-looking statements, except as required by law. For more information, refer to the "Risk Factors" section of the Company's filings at www.sedarplus.ca.
Trademarks: Mavenclad® is a registered trademark of EMD Serono, Inc. BioNxt Solutions Inc. is not affiliated with or endorsed by EMD Serono.
SOURCE: BioNxt Solutions Inc.
View the original press release on accesswire.com
BioNxt Solutions Inc.
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
GA-ASI and USN Test Expanded Sonobuoy Dispensing System For MQ-9B SeaGuardian(R)13.1.2026 19:00:00 CET | Press release
SAN DIEGO, CALIFORNIA / ACCESS Newswire / January 13, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) and the U.S. Navy continue to expand the Anti-Submarine Warfare (ASW) capability of the MQ-9B SeaGuardian® Unmanned Aircraft System (UAS). Flight test was performed on December 17 and featured Sonobuoy Dispensing System (SDS) pods, more than previously tested, doubling the number of sonobuoys available. "Expanding sonobuoy capacity, including Multi-static Active Coherent (MAC) technology for SeaGuardian, has been an integral part of our advanced ASW strategy to broaden and enhance search areas," said GA-ASI President David R. Alexander. "The wider maritime coverage our MQ-9B's ASW capability provides is extremely valuable to our customers." Sonobuoys are naval sensors that drop from an aircraft into the ocean and help detect submarines. The SeaGuardian deployed AN/SSQ-36 Bathythermal, AN/SSQ-53G Directional Frequency Analysis and Recording (DIFAR) (passive), and AN/SSQ-62F D
Hirth Engines and ePropelled Announce Strategic Collaboration to Advance High-Efficiency Propulsion Systems13.1.2026 15:00:00 CET | Press release
Unifying Strengths to Address a Growing Market COVENTRY, UK / ACCESS Newswire / January 13, 2026 / Hirth Engines, a globally recognized leader in two-stroke engine technology, and ePropelled, an innovator in high-efficiency intelligent electric propulsion and power generation systems , today announced a strategic collaboration aimed at delivering the next generation of hybrid propulsion solutions for the UAV, aerospace, defense, and specialized mobility markets. Driven by increasing demand for reliable, lightweight, and energy-efficient propulsion systems, the partnership brings together Hirth's decades-long expertise in advanced combustion engines with ePropelled's pioneering electric propulsion and power management technologies. Together, the companies will develop integrated hybrid systems designed to offer unmatched performance, extended mission endurance, and greater operational flexibility. Unifying Strengths to Address a Growing Market Under this collaboration, Hirth Engines wil
Polaris Renewable Energy Announces Q4 and Annual 2025 Investor Call Details13.1.2026 15:00:00 CET | Press release
TORONTO, ONTARIO / ACCESS Newswire / January 13, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company") is pleased to announce it will be holding its Earnings Conference Call and Webcast to report its Q4 and annual 2025 Earnings Results on Thursday, February 19th, 2026, at 10:00 am EST. To listen to the call, please dial Toll Free 1 888-506-0062 or International Toll-Free Number 973-528-0011 entry code 743835. or URL: https://www.webcaster4.com/Webcast/Page/2773/51835 A digital recording of the earnings call will be available for replay two hours after the call's completion. Replay Call Information: Toronto: 1 877-481-4010, Passcode: 51835 International (toll-free): 1 919-882-2331, Passcode: 51835 Encore Replay Expiration Date: March 05, 2026 About Polaris Renewable Energy Inc. Polaris Renewable Energy Inc. is a Canadian publicly traded company engaged in the acquisition, development, and operation of renewable energy projects in Latin America and the Caribbean. We
Global Sports Brand U.S. Polo Assn. Announced as Official Jersey and Apparel Sponsor for the Legendary Snow Polo World Cup St. Moritz13.1.2026 13:00:00 CET | Press release
WEST PALM BEACH, FL AND ST. MORITZ, SWITZERLAND / ACCESS Newswire / January 13, 2026 / U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), will make its debut as the Official Jersey and Apparel Sponsor of the 41stSnow Polo World Cup St. Moritz, taking place January 23-25, 2026, on the iconic frozen lake of St. Moritz. U.S. Polo Assn.'s inaugural partnership with the world's most prestigious and legendary snow polo tournament underscores the brand's authentic ties to the game and its continued commitment to supporting polo around the world.Photo Caption: Snow Polo World Cup St. Moritz, with Official Jersey and Apparel Sponsor, U.S. Polo Assn. Photo Credit: Christian Sommer Snow Polo World Cup St. Moritz 2026 is already shaping up to be a record-breaking year, with unprecedented demand for tickets, elite international players, and global attention focused on one of the world's most high-profile polo tournaments played on snow. This event will see more
Clean Air Metals Announces 2026 Strategic Objectives in Historically Strong PGE and Copper Markets13.1.2026 01:10:00 CET | Press release
THUNDER BAY, ON / ACCESS Newswire / January 12, 2026 / Clean Air Metals Inc. ("Clean Air Metals" or the "Company") (TSXV:AIR)(FRA:CKU0(OTCQB:CLRMF) is pleased to provide an overview of its 2026 objectives and highlights of 2025, for its 100%-owned Thunder Bay North ("TBN") Critical Minerals Project in Northwestern Ontario. Critical Project Advancement Objectives Spot prices for platinum, copper and palladium have appreciated by 70% (1000 $/oz), 25% (1.20 $/lb) and 50% 624($/oz) respectively versus study prices, since the results of the Preliminary Economic Assessment (PEA) were announced in the October 9th release. Using the financial model published in the PEA and applying current spot metal prices (as of January 6th), the TBN project shows a $708M1 NPV8 and a pre-tax IRR of 100% (post-tax NPV8 = $494M1 and IRR = 84%).This is a significant improvement in the project outlook in comparison to the PEA results that featured a $219.4M2 pre-tax NPV8 and a pre-tax IRR of 39%. This year, cons
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom